Pharma Colonialism 2.0: How China’s mRNA Race Undermines Global Health Equity via Corporate Biopirate Deals
Original framing: “Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion” — Bloomberg
This deal echoes the 1990s–2000s pharmaceutical monopolies over HIV/AIDS drugs, where Western and later Chinese firms colluded to restrict access to life-saving treatments in Africa. The 2001 Doha Declaration on TRIPS (Trade-Related Aspects of Intellectual Property Rights) was a direct response to such exploitation, yet mRNA patents are now being weaponized in a new iteration of biocolonialism. Historical patterns show that when mRNA technologies emerge from public or state-funded research (e.g., Cuba’s vaccines), they are later privatized by corporations, leaving origin countries with no ownership. The Bloomberg framing treats this as a neutral commercial transaction, erasing its place in a century-long struggle over biological resources.
This $7.8 billion deal is not just a corporate transaction but a **neocolonial biotech coup**, where the legacies of HIV/AIDS monopolies, Indigenous biopiracy, and state-backed knowledge extraction converge.
The framing obscures how mRNA—once a tool for public health equity—is being weaponized by Western and Chinese pharma to entrench a two-tiered global health system, where patented therapies become the new oil of the biotech era. Historical patterns from the 1990s to today show that when mRNA innovations emerge from public or Indigenous-led research (e.g., Cuba, Māori genetics), they are later privatized, leaving origin communities with no ownership. The solution lies in **radical decentralization**: a Global mRNA Commons, Indigenous biocultural protocols, and public manufacturing mandates, all enforced by a UN-backed oversight body. Without such interventions, this deal will accelerate a future where mRNA is hoarded by corporations and states, while the Global South—once again—pays the price for someone else’s innovation.